Leukemia
Fixed-duration ibrutinib-venetoclax induces deep responses in treatment-naive CLL
Fixed-duration first-line treatment with ibrutinib plus venetoclax induced deep, durable responses among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of the phase 2 CAPTIVATE study.
Zanubrutinib outperforms ibrutinib in advanced CLL, small lymphocytic lymphoma
Zanubrutinib induced a superior overall response rate compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to study results.
Aspacytarabine a potential first-line option for chemotherapy-ineligible patients with AML
The novel antimetabolite aspacytarabine appeared safe and efficacious as first-line therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy, according to a study presented during the virtual ASCO Annual Meeting.
Donor-derived CAR T cells show encouraging efficacy for advanced T-cell ALL
Ninety-five percent of patients with relapsed or refractory T-cell acute lymphoblastic leukemia responded to therapy with donor-derived chimeric antigen receptor T cells, according to results of a phase 1 study.
Acalabrutinib confers equal PFS with less toxicity vs. ibrutinib in previously treated CLL
Acalabrutinib proved noninferior to ibrutinib in terms of PFS and resulted in less cardiotoxicity and fewer discontinuations due to adverse effects in a head-to-head trial among patients with previously treated chronic lymphocytic leukemia.
CAR T-cell therapy shows ‘high and durable response rates’ in adults with B-cell ALL
Brexucabtagene autoleucel induced an overall remission rate of greater than 70% among adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a single infusion of the therapy, according to phase 2 study results.
Novel CAR-T induces response prior to HSCT in younger patients with advanced AML
A novel chimeric antigen receptor T-cell therapy showed clinically relevant antitumor activity in nine of 11 younger patients with relapsed or refractory acute myeloid leukemia, according to early data from a phase 1/phase 2 study.
Ponatinib plus blinatumomab may provide chemotherapy-free regimen for leukemia subset
Ponatinib and blinatumomab induced high rates of complete molecular remission among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to research presented during the virtual ASCO Annual Meeting.
Mayo Clinic appoints executive director of cancer programs
Cheryl Willman, MD, has been named executive director of Mayo Clinic cancer programs.
FDA grants orphan drug designation to gamma-delta T-cell therapy for AML
The FDA cleared an investigational new drug application for GDX012, a gamma-delta T-cell therapy, for patients with previously treated hematologic malignancies.